NCT01053936View on ClinicalTrials.gov

Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

February 28, 2011

Conditions
Renal Insufficiency, ChronicDiabetes Mellitus, Type 2
Interventions
DRUG

Bardoxolone methyl (amorphous dispersion)

Oral, once daily

Trial Locations (26)

15224

Pittsburgh

20036

Washington D.C.

27103

Winston-Salem

28557

Morehead City

30114

Canton

30901

Augusta

33401

West Palm Beach

33511

Brandon

33952

Port Charlotte

36106

Montgomery

37304

Chattanooga

55430

Brooklyn Center

60616

Chicago

61603

Peoria

75390

Dallas

75402

Greenville

77099

Houston

78215

San Antonio

78404

Corpus Christi

85012

Phoenix

85284

Tempe

91773

San Dimas

91942

La Mesa

92505

Riverside

98003

Federal Way

02904

Providence

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY